Clinical Trials Browser

Neoplasm, Residual × Control Groups × Clear all

NCT06301425 2024-07-10

MRD Response-adapted Allo-HSCT for Adverse-risk AML

Phase NA Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual